Interestingly, the characterization of metabolic profiles in AIP experimental models and humans has highlighted alterations in glucose and lipid metabolism, insulin resistance (IR), and hepatic mitochondrial dysfunction, which offers the possibility of considering insulin and insulin-mimetics for the clinical management of AIP [16,17,18]. The gene discussed is INS; the disease is autoimmune pancreatitis.